University of Utah Research Foundation

Johns Hopkins University

Cancer Institute

Other

Imperial Chemical Industries Limited

Zeneca Limited

Cancer Institute, Japanese Foundation for Cancer Research

The Univ. of Utah

Japanese Foundation for Cancer Research Cancer Institute

Zeneca Pharmaceuticals

Astrazeneca United Kingdom, Ltd.

Raymond L White

Bert Vogelstein

Kenneth W Kinzler

Yusuke Nakamura

Hans Albertsen

Alexander Fred Markham

Rakesh Anand

Geoff Joslyn

Philip John Hedge

Mary Carlson

Joanna Groden

Andrew Thliveris

Kalvin Watson

Peter O'Connell

Mark F Leppert

Richard M Cawthon

David H Viskochil

Midvale

Ying Li

Lisa Spirio

Joanna L Groden

Robert Weiss

Margaret Robertson

Therese Tuohy

Yusuke Nakumura

Yusuka Nakamura

Andrew Thilveris

A human gene termed APC is disclosed. Methods and kits are provided for assessing mutations of the APC gene in human tissues and body samples. APC mutations are found in familial adenomatous polyposis patients as well as in sporadic colorectal cancer patients. APC is expressed in most normal tissues. These results suggest that APC is a tumor suppressor.

APC antibodies

APC Antibodies

Diagnosis for mutant APC by immunoassay

Detection of APC proteins

An improved compact disc holder is disclosed for the safe and convenient temporary storage of a digital optical compact disc. The disc holder may be adhesive backed for conveniently mounting to a flat surface or alternately the disc holder may be incorporated into a weighted base to be self supporting. Advantageously, the disc holder provides one or more surfaces for the prominent display of an advertisement.

Compact disc holder

The present invention relates to a functional screen assay for nonsense or frameshift mutations that allows genes of interest to be scanned. This assay is based on the cloning of segments of the gene of interest in-frame with a sequence coding for a marker followed by screening for the level of expression of the marker. Individuals at risk for any one of a number of genetic diseases, which are associated with such nonsense or frameshift mutations, can be quickly screened for chain-terminating mutations introduced by these nonsense and frameshift mutations. At present, scanning of many genes for mutations requires significant effort because the genes are large and most mutations are unique. Therefore, this assay offers a powerful option for the diagnosis of many genetic diseases.

Alleles

A new human gene termed MCC is disclosed. Antibody based methods and kits are provided for assessing mutations of the MCC gene in human tissues and body samples. Gross rearrangement and point mutations in MCC are observed in human tumor cells. MCC is expressed in most normal tissues. These results suggest that MCC is a tumor suppressor.

Diagnosis with MCC

APC (adenomatous polyosis coli) protein

A new human gene termed MCC is disclosed. Methods and kits are provided for assessing mutations of the MCC gene in human tissues and body samples. Gross rearrangement and point mutations in MCC are observed in human tumor cells. MCC is expressed in most normal tissues. These results suggest that MCC is a tumor suppressor.

Gene therapy with MCC

Methods are provided for assessing mutations of the APC gene in human tissues and body samples. APC mutations are found in familial adenomatous polyposis patients as well as in sporadic colorectal cancer patients. APC is expressed in most normal tissues. APC is a tumor suppressor.

Detection of inherited and somatic mutations of APC gene in colorectal

The present invention is directed to somatic mutations of the NF1 gene which are found in human tumors. In addition, the present invention is directed to methods of screening humans to determine those having somatic mutations in the NF1 gene in tumors. Finally, the invention is directed to a method of treating a human having a tumor with a somatic mutation in the NF1 gene by restoring natural regulation of ras proteins.

Somatic mutations in neurofibromatosis type 1 gene in human tumors

A new human gene termed MCC is disclosed. Methods and kits are provided for assessing mutations of the MCC gene in human tissues and body samples. Gross rearrangement and point mutations in MCC are observed in human tumor cells. MCC is expressed in most normal tissues. These results suggest that MCC is a tumor suppressor. A MCC protein and antibody are disclosed.

MCC protein and antibody

Growing community of inventors

Salt Lake City, UT, United States of America

Raymond L White